These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 39209000)

  • 1. Identification of Senkyunolide I as a novel modulator of hepatic steatosis and PPARα signaling in zebrafish and hamster models.
    Li Q; Sheng J; Baruscotti M; Liu Z; Wang Y; Zhao L
    J Ethnopharmacol; 2025 Jan; 336():118743. PubMed ID: 39209000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.
    Huang Y; Lang H; Chen K; Zhang Y; Gao Y; Ran L; Yi L; Mi M; Zhang Q
    Appl Physiol Nutr Metab; 2020 Mar; 45(3):227-239. PubMed ID: 31173696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Puerarin ameliorates hepatic steatosis by activating the PPARα and AMPK signaling pathways in hepatocytes.
    Kang OH; Kim SB; Mun SH; Seo YS; Hwang HC; Lee YM; Lee HS; Kang DG; Kwon DY
    Int J Mol Med; 2015 Mar; 35(3):803-9. PubMed ID: 25605057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel Alisma orientale extract alleviates non-alcoholic steatohepatitis in mice via modulation of PPARα signaling pathway.
    Xie Y; Jin Y; Wen J; Li G; Huai X; Duan Y; Ni F; Fu J; Li M; Li L; Yan M; Cao L; Xiao W; Yang H; Wang ZZ
    Biomed Pharmacother; 2024 Jul; 176():116908. PubMed ID: 38850668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
    Araújo S; Soares E Silva A; Gomes F; Ribeiro E; Oliveira W; Oliveira A; Lima I; Lima MDC; Pitta I; Peixoto C
    Eur J Pharmacol; 2016 Oct; 788():306-314. PubMed ID: 27349145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats.
    Li S; Liao X; Meng F; Wang Y; Sun Z; Guo F; Li X; Meng M; Li Y; Sun C
    PLoS One; 2014; 9(1):e86724. PubMed ID: 24489777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
    Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
    J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xiaozhi formula attenuates non-alcoholic fatty liver disease by regulating lipid metabolism via activation of AMPK and PPAR pathways.
    You L; Wang T; Li W; Zhang J; Zheng C; Zheng Y; Li S; Shang Z; Lin J; Wang F; Qian Y; Zhou Z; Kong X; Gao Y; Sun X
    J Ethnopharmacol; 2024 Jul; 329():118165. PubMed ID: 38588984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of perfluorooctanoate on high fat diet induced non-alcoholic fatty liver disease in mice.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2019 Mar; 416():1-14. PubMed ID: 30711707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procyanidin B2 ameliorates free fatty acids-induced hepatic steatosis through regulating TFEB-mediated lysosomal pathway and redox state.
    Su H; Li Y; Hu D; Xie L; Ke H; Zheng X; Chen W
    Free Radic Biol Med; 2018 Oct; 126():269-286. PubMed ID: 30142454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis.
    Yang RX; Pan Q; Liu XL; Zhou D; Xin FZ; Zhao ZH; Zhang RN; Zeng J; Qiao L; Hu CX; Xu GW; Fan JG
    Lipids Health Dis; 2019 Oct; 18(1):179. PubMed ID: 31639005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HIF-2α/PPARα pathway is essential for liraglutide-alleviated, lipid-induced hepatic steatosis.
    Wang H; Wang L; Li Y; Luo S; Ye J; Lu Z; Li X; Lu H
    Biomed Pharmacother; 2021 Aug; 140():111778. PubMed ID: 34062416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid attenuates high-fat diet-induced steatohepatitis
    Xin FZ; Zhao ZH; Zhang RN; Pan Q; Gong ZZ; Sun C; Fan JG
    World J Gastroenterol; 2020 May; 26(18):2203-2220. PubMed ID: 32476787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydromyricetin ameliorates hepatic steatosis and insulin resistance via AMPK/PGC-1α and PPARα-mediated autophagy pathway.
    Yang Y; Qiu W; Xiao J; Sun J; Ren X; Jiang L
    J Transl Med; 2024 Mar; 22(1):309. PubMed ID: 38532480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
    Huang K; Du M; Tan X; Yang L; Li X; Jiang Y; Wang C; Zhang F; Zhu F; Cheng M; Yang Q; Yu L; Wang L; Huang D; Huang K
    J Hepatol; 2017 May; 66(5):962-977. PubMed ID: 27979751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the effect of a mixture of two main conjugated linoleic acid isomers on hepatic steatosis in HepG2 cellular model.
    Jalilian A; Golmohammadi T; Meshkani R; Koushki M; Eivazi N; Khorzoughi RB; Fard SRH; Paknejad M
    Mol Biol Rep; 2021 Feb; 48(2):1359-1370. PubMed ID: 33580458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD38 Deficiency Protects Mice from High Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Activating NAD
    Xie L; Wen K; Li Q; Huang CC; Zhao JL; Zhao QH; Xiao YF; Guan XH; Qian YS; Gan L; Wang LF; Deng KY; Xin HB
    Int J Biol Sci; 2021; 17(15):4305-4315. PubMed ID: 34803499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. β-patchoulene improves lipid metabolism to alleviate non-alcoholic fatty liver disease via activating AMPK signaling pathway.
    Xu N; Luo H; Li M; Wu J; Wu X; Chen L; Gan Y; Guan F; Li M; Su Z; Chen J; Liu Y
    Biomed Pharmacother; 2021 Feb; 134():111104. PubMed ID: 33341045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theobromine ameliorates nonalcoholic fatty liver disease by regulating hepatic lipid metabolism via mTOR signaling pathway in vivo and in vitro.
    Wei D; Wu S; Liu J; Zhang X; Guan X; Gao L; Xu Z
    Can J Physiol Pharmacol; 2021 Aug; 99(8):775-785. PubMed ID: 33290156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway.
    Wang LF; Wang XN; Huang CC; Hu L; Xiao YF; Guan XH; Qian YS; Deng KY; Xin HB
    Lipids Health Dis; 2017 Apr; 16(1):82. PubMed ID: 28449683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.